Adenocarcinoma in situ, minimally invasive adenocarcinoma and invasive adenocarcinoma of lung
Adenocarcinoma in situ, minimally invasive adenocarcinoma and invasive adenocarcinoma of the lung are relatively new classification entities which replace the now-defunct term bronchoalveolar carcinoma (BAC).
In 2011 the International Association for the Study of Lung Cancer (IASLC) and several other societies jointly revised the classification for adenocarcinoma of lung 13. The new classification strategy is based on a multidisciplinary approach to the diagnosis of lung adenocarcinoma. The terms bronchoalveolar carcinoma and mucinous and non-mucinous bronchoalveolar carcinoma have been rendered obsolete.
Before a general discussion of the topic, it is worth highlighting some of the updated terminology and concepts, as for many who were taught the term bronchoalveolar carcinoma, some adjustment will be necessary 5:
adenocarcinoma in situ of lung (AIS) (≤3 cm) has a number of subtypes
- the most common subtype is non-mucinous and rarely mucinous or mixed subtypes
- histological pattern: no growth pattern other than lepidic and no feature of necrosis or invasion
minimally invasive adenocarcinoma of lung (MIA) ≤3 cm
- describes small solitary adenocarcinomas with either pure lepidic growth or predominant lepidic growth with ≤5 mm of stromal invasion
The two invasive adenocarcinomas previously termed non-mucinous and mucinous bronchoalveolar carcinoma have been renamed:
- lepidic-predominant adenocarcinoma describes invasive adenocarcinoma with a predominant lepidic pattern with >5 mm invasion; formerly known as non-mucinous bronchoalveolar carcinoma
- invasive mucinous adenocarcinoma is a variant of invasive adenocarcinoma; formerly known as mucinous bronchoalveolar carcinoma
AIS and MIA are an uncommon type of bronchial carcinoma which occurs most frequently among non-smokers, women and Asians. It is a subtype of adenocarcinoma, but has a significantly different presentation, treatment and prognosis. Adenocarcinoma in situ and minimally invasive adenocarcinoma represent between 2-14% of all primary pulmonary malignancies 11. There is no significant gender predilection, unlike other lung cancer types which are more prevalent in men.
Presentation is often insidious, and a large proportion (50%) of patients may be asymptomatic at the time of detection 1. Alternatively, as these tumours can produce large quantities of mucus, patients may present with bronchorrhea.
Persistent consolidation for weeks despite appropriate antimicrobial therapy should raise the suspicion of a neoplastic process. CT or guided biopsy may be planned in such cases.
Adenocarcinoma in situ: ≤3 cm, demonstrates a lepidic growth pattern, spreading along the walls of the lung without destroying the underlying architecture. In addition, they are characterised by the absence of stromal, vascular or pleural invasion.
Minimally invasive adenocarcinoma: ≤3 cm, describes small solitary adenocarcinomas with either pure lepidic growth or predominant lepidic growth with ≤5 mm of stromal invasion.
Three pathological subtypes are recognised 3:
- mucinous: goblet cell (mucus secreting), often multi-centric
There are three recognised radiographic patterns 1
- single mass or nodular form (commonest): ~45 %
- consolidative form: ~30 %
- multinodular form: ~25 %
May show segmental or lobar consolidation with chronic unilateral airspace opacification and air bronchograms. Can also present as a pulmonary nodule, mass or a cluster of diffuse nodules 1,2. The nodular form (commonest) can be indistinguishable from another adenocarcinoma subtype or inflammatory granuloma on plain film 1.
The appearance on CT depends on its pattern of growth; hence, it may appear as:
- a peripheral nodule
- commonest appearance
- typically solitary and well circumscribed 5
- the nodule may be surrounded by a halo of ground-glass opacity, the so-called fried egg sign
- a focal area of ground glass (early sign)
- heterogeneous attenuation
- a region of ground glass, with or without consolidation
- hilar and mediastinal adenopathy and pleural effusion are uncommon
18F-FDG-PET is often negative 6,7.
Treatment and prognosis
Surgical resection is required with a lobectomy or pneumonectomy.
Overall, tumours that demonstrate only lepidic growth tend to be indolent, with a high 5-year survival. However, solid, invasive components are frequently present and despite radical treatment, recurrence rates are high. Mucinous subtypes have worse prognosis 4, probably due to aerogenous spread that forms infiltrating, multifocal, or satellite tumours 11.
History and etymology
The entity formerly known as bronchoalveolar carcinoma was first described by Malassez in 1876, as a bilateral, multinodular form of malignant lung tumour 11-12.
The shifting terminology of non-invasive adenocarcinoma reflects both an increased utilization of immunohistochemical testing, as well as advances in personalized cancer treatment. Beginning with the 1999 World Health Organization guidelines, there has been attempt to isolate purely non-invasive and minimally-invasive adenocarcinoma from more advanced adenocarcinoma, due to uniquely favorable prognosis in the former 14. Prior to the 2011 IASLC/ATS/ERS update, various forms of invasive disease remained lumped into the BAC category. Thus, scrapping the BAC classification was intended to further remove ambiguity.
General imaging differential considerations are broad, so it is useful to consider differentials for specific patterns, which include:
- differential of chronic alveolar opacity
- differential of a solitary pulmonary nodule
- differential of ground glass opacity
- 1. Lee KS, Kim Y, Han J et-al. Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings. Radiographics. 17 (6): 1345-57. Radiographics (abstract) - Pubmed citation
- 2. Hill CA. Bronchioloalveolar carcinoma: a review. Radiology. 1984;150 (1): 15-20. Radiology (abstract) - Pubmed citation
- 3. Mihara N, Ichikado K, Johkoh T et-al. The subtypes of localized bronchioloalveolar carcinoma: CT-pathologic correlation in 18 cases. AJR Am J Roentgenol. 1999;173 (1): 75-9. AJR Am J Roentgenol (abstract) - Pubmed citation
- 4. Raz DJ, He B, Rosell R et-al. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer. 2006;7 (5): 313-22. Pubmed citation
- 5. Collins J, Stern EJ. Chest radiology, the essentials. Lippincott Williams & Wilkins. (2007) ISBN:0781763142. Read it at Google Books - Find it at Amazon
- 6. Chen CJ, Lee BF, Yao WJ et-al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008;191 (2): 475-9. doi:10.2214/AJR.07.3457 - Pubmed citation
- 7. Higashi K, Ueda Y, Seki H et-al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J. Nucl. Med. 1998;39 (6): 1016-20. J. Nucl. Med. (abstract) - Pubmed citation
- 8 .Oda S, Awai K, Liu D et-al. Ground-glass opacities on thin-section helical CT: differentiation between bronchioloalveolar carcinoma and atypical adenomatous hyperplasia. AJR Am J Roentgenol. 2008;190 (5): 1363-8. doi:10.2214/AJR.07.3101 - Pubmed citation
- 9. Adler B, Padley S, Miller RR et-al. High-resolution CT of bronchioloalveolar carcinoma. AJR Am J Roentgenol. 1992;159 (2): 275-7. AJR Am J Roentgenol (abstract) - Pubmed citation
- 10. Patsios D, Roberts HC, Paul NS et-al. Pictorial review of the many faces of bronchioloalveolar cell carcinoma. Br J Radiol. 2007;80 (960): 1015-23. doi:10.1259/bjr/52225107 - Pubmed citation
- 11. Liu YY, Chen YM, Huang MH et-al. Prognosis and recurrent patterns in bronchioloalveolar carcinoma. Chest. 2000;118 (4): 940-7. doi:10.1378/chest.118.4.940 - Pubmed citation
- 12. Malassez, L Examen histologique d’un cas de cancer encephaloide du poumon (epithelioma). Arch Physiol Norm Pathol 1876;3,353-372
- 13. Travis WD, Brambilla E, Noguchi M et-al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6 (2): 244-85. doi:10.1097/JTO.0b013e318206a221 - Pubmed citation
- 14. E. Brambilla, W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato. The new World Health Organization classification of lung tumours. (2001) European Respiratory Journal. 18 (6): 1059. doi:10.1183/09031936.01.00275301 - Pubmed